- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Aducanumab Might Cause Brain Swelling in 35% of Alzheimer's disease patients: JAMA
Aduhelm (Aducanumab) becomes the first treatment approved for Alzheimer's disease in almost 20 years. However, a recent safety analysis suggests that 41.3 per cent of all trial participants experienced some kind of brain imaging abnormality throughout the study. The study findings were published in the journal JAMA Neurology on November 22, 2021.
The controversies around Aduhelm started since the early phase of approval as an independent data monitoring committee had looked at the early results and concluded the drug didn't seem to be working. Later, Biogen revealed that the findings were premature and further investigations showed positive results from patients exposed to higher doses of the drug for longer periods of time. Based on on two phase III studies, EMERGE and ENGAGE findings FDA granted approval for aduhelm.
After approval Aduhelm transverse a rocky road as FDA went ahead despite a score of specialists and senior FDA officials pointing out that it was unclear whether Aduhelm would benefit patients. Followed later by the death of a 75-year-old trial participant and Biogen responded to the report saying the causes of death remain unknown at this time. Now, several months later, the aducanumab story continues after the findings of the secondary analysis.
Dr Stephen Salloway and his team conducted a secondary analysis of data from the EMERGE and ENGAGE trials, which were 2 double-blind, placebo-controlled, parallel-group, phase 3 randomized clinical trials that compared low-dose and high-dose aducanumab treatment with placebo. They included a total of 3285 participants with Alzheimer disease who received one or more doses of placebo (n = 1087) or aducanumab (n = 2198; 2752 total person-years of exposure) during the placebo-controlled period.
The major outcome assessed was the incidence of amyloid-related imaging abnormalities (ARIA) which was monitored using brain magnetic resonance imaging. Associated symptoms were reported as adverse events.
Key Findings of the Study:
- During the placebo-controlled period, the researchers noted that 41.3% experienced ARIA, with serious cases occurring in 14 patients (1.4%).
- They also noted that ARIA-edema (ARIA-E) was the most common adverse event (35.2%), and 72.7% occurred within the first 8 doses of aducanumab; 26.0%with an event exhibited symptoms.
- They observed that most of those affected by the ARIA-edema did not report any symptoms, but among those who did, headache, confusion and dizziness were commonly experienced.
- They found that the incidence of ARIA-E was highest in aducanumab-treated participants who were apolipoprotein E ε4 allele carriers.
- They further noted that most events (98.2%) among those with ARIA-E resolved radiographically and 82.8% resolved within 16 weeks.
- In the placebo group, they observed 2.7% had ARIA-E. 19.1% had ARIA-microhemorrhage and 14.7% ARIA–superficial siderosis.
The study is one of the first formal publications of safety data to stem from the two final-stage trials of Aduhelm.
The authors concluded, "In this integrated safety data set from EMERGE and ENGAGE, the most common adverse event in the 10-mg/kg group was ARIA-E, which occurred in 362 of the 1029 patients (35.2%) in the 10-mg/kg group with at least 1 postbaseline MRI scan, with 94 patients (26.0%) experiencing associated symptoms. The most common associated symptom was headache."
For further information:
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751